Elevara Medicines

About Elevara Medicines

Elevara Medicines is a clinical‑stage biotechnology company developing oral small‑molecule therapies that target fibroblast‑like synoviocytes to boost remission rates in rheumatoid arthritis. Their lead candidate, ELV001, a CDK4/6 inhibitor, is designed to work synergistically with existing DMARDs and is being evaluated in a global Phase 2b START‑SYNERGY trial across the United States, South Africa, and several European countries.